Table 1. Characteristics of the sample population.

	Entire cohort (n = 43,802)		Patients using statins (≥ 28 cDDDs; n = 10,086)		Patients not using statins (< 28 cDDDs; n = 33,716)		Pa
	n	%	n	%	n	%
Age, years (mean ± SD)	62.92 (13.18)		61.55 (10.97)		63.33 (13.74)		< 0.001
40–54	14458	33.01	3180	31.53	11278	33.45	< 0.001
55–64	9644	22.02	2899	28.74	6745	20.01
65–74	10455	23.87	2777	27.53	7678	22.77
≥ 75	9245	21.11	1230	12.20	8015	23.77
Sex
Female	19715	45.01	5150	51.06	14565	43.20	< 0.001
Male	24087	54.99	4936	48.94	19151	56.80
CCI+
0	11279	25.75	2586	25.64	8693	25.78	< 0.001
1	12597	28.76	3014	29.88	9583	28.42
2	9075	20.72	2195	21.76	6880	20.41
≥ 3	10851	24.77	2291	22.71	8560	25.39
Diabetes
No	33491	76.46	6819	67.61	26672	79.11	< 0.001
Yes	10311	23.54	3267	32.39	7044	20.89
Hypertension
No	22067	50.38	4158	41.23	17909	53.12	< 0.001
Yes	21735	49.62	5928	58.77	15807	46.88
Dyslipidemia
No	31731	72.44	5785	57.36	25946	76.95	< 0.001
Yes	12071	27.56	4301	42.64	7770	23.05
Nonstatin lipid-lowering drugs
< 28 days	39267	89.65	7212	71.51	32055	95.07	< 0.001
28–365 days	3186	7.27	1923	19.07	1263	3.75
> 365 days	1349	3.08	951	9.43	398	1.18
Metformin
< 28 days	35961	82.10	6286	62.32	29675	88.01	< 0.001
28–365 days	2684	6.13	964	9.56	1720	5.10
> 365 days	5157	11.77	2836	28.12	2321	6.88
ACEI
< 28 days	23928	54.63	3066	30.40	20862	61.88	< 0.001
28–365 days	7925	18.09	1928	19.12	5997	17.79
> 365 days	11949	27.28	5092	50.49	6857	20.34
Aspirin
< 28 days	28319	64.65	4161	41.26	24158	71.65	< 0.001
28–365 days	7385	16.86	2296	22.76	5089	15.09
> 365 days	8098	18.49	3629	35.98	4469	13.25
Urbanization level
Urban	30539	69.72	7208	71.47	23331	69.20	< 0.001
Suburban	8914	20.35	1920	19.04	6994	20.74
Rural	4349	9.93	958	9.50	3391	10.06
Monthly income (NT$)
0	3464	7.91	795	7.88	2669	7.92	< 0.001
1–21,000	15001	34.25	3067	30.41	11934	35.40
21,000–33,300	12904	29.46	3165	31.38	9739	28.89
≥ 33,301	12433	28.38	3059	30.33	9374	27.80

^aComparison between statin use and no statin use.

⁺CCI: Charlson comorbidity index.